What STDs Can Go Undetected Without Symptoms?

Most of the common sexually transmitted infections can silently persist for weeks, months, or even years without producing noticeable symptoms. Chlamydia, gonorrhea, herpes, HPV, trichomoniasis, syphilis, HIV, and the lesser-known Mycoplasma genitalium all have well-documented asymptomatic phases during which a person can unknowingly pass the infection to partners. The proportion of cases that never cause symptoms is surprisingly high for some of these, and the consequences of missing them range from chronic pain to infertility to cancer.

Chlamydia and Gonorrhea

These two bacterial infections are the textbook examples of silent STIs. In a study that estimated the proportion of infections that never produce symptoms, roughly 77% of chlamydia cases and about 45% of gonorrhea cases were never symptomatic. Even more striking, the vast majority of untreated cases went untreated precisely because the person never felt anything wrong: an estimated 95% of untreated chlamydia and 86% of untreated gonorrhea fell into that category.¹ In plain terms, if you have chlamydia, the odds are good you will never know it unless you get tested.

Gonorrhea adds another layer of difficulty. It can colonize the throat and rectum without causing any local irritation, which means routine genital testing alone can miss it. In a study of college-aged men who have sex with men, about 3.5% tested positive for pharyngeal gonorrhea using sensitive molecular testing, even though standard culture came back negative for all of them.² That mismatch between culture and newer molecular tests is one reason older screening methods systematically undercount non-genital infections.

Herpes Simplex Virus

Genital herpes, caused primarily by HSV-2, is famous for its outbreaks of painful blisters, but most of the time the virus is doing its work invisibly. In a carefully tracked study, participants reported no genital lesions on about 90% of the days they were followed, yet the virus was detectable on the skin on roughly 12% of those lesion-free days.³ This is what clinicians call subclinical shedding: the virus reaches the skin surface and can be transmitted to a partner without the infected person feeling or seeing anything.

People who have never had a recognized outbreak still shed the virus, though at a somewhat lower rate. That same study found subclinical shedding on about 9% of days among people with no history of symptoms, compared with about 13% among those who had experienced outbreaks.³ This means that a sizable portion of new herpes transmissions come from people who genuinely do not know they carry the virus. Standard STI panels do not routinely include herpes blood tests, so many infections go undiagnosed indefinitely.

Human Papillomavirus

HPV is arguably the most silently prevalent sexually transmitted infection worldwide. Over 100 types exist, and a subset classified as “high risk” are responsible for nearly all cervical cancers. High-risk HPV DNA is found in more than 99.7% of cervical cancers, with HPV16 being the single most common type in both early-stage lesions and advanced disease.⁴ Yet the infection itself almost never causes symptoms. There is no fever, no discharge, and no pain. Most people clear the virus on their own over a year or two without ever knowing they had it. The trouble is that a minority do not clear it, and persistent high-risk HPV infection is the gateway to cervical precancer and, eventually, invasive cancer.

In a study of 3,000 women in a high-risk region for cervical cancer, the high-risk HPV infection rate was about 8.7%, and the persistent infection rate was 7.5%.⁵ Because HPV produces no warning signs during its most dangerous phase, cervical screening programs (Pap smears and HPV co-testing) are the primary tool for catching precancerous changes before they progress. Vaccination has dramatically reduced new infections in populations with high uptake, but it does not help people already infected, which is why screening remains essential even for vaccinated individuals.

Trichomoniasis

Trichomoniasis, caused by the parasite Trichomonas vaginalis, is one of the most common curable STIs globally, and one of the most frequently overlooked. In women, over 80% of infections are asymptomatic, and those silent infections can persist for months or even years.⁶ Men tend to clear symptomatic infections on their own within about ten days, which further reduces the chance of diagnosis: a man may carry the parasite just long enough to pass it along before the infection resolves spontaneously.

Because trichomoniasis rarely makes the infected person uncomfortable, many cases are only discovered incidentally during screening for other conditions. This matters for pregnancy in particular. A cost-effectiveness analysis found that routine screening and treatment of trichomoniasis in asymptomatic pregnant people could prevent an estimated 7,300 preterm births, 284 neonatal deaths, and 63 cases of neonatal neurodevelopmental delay, all at a very favorable cost per quality-adjusted life-year gained.⁷ Despite this, trichomoniasis screening is not universally recommended in prenatal care the way chlamydia screening is.

Mycoplasma Genitalium

This bacterium is less well known than chlamydia or gonorrhea but is increasingly recognized as a significant sexually transmitted pathogen. In a cohort of HIV-positive men who have sex with men followed over time, Mycoplasma genitalium had the highest period prevalence among all STIs screened, at about 20% of participants testing positive at least once. Only two of those 30 infected participants, about 7%, were symptomatic at the time of diagnosis.⁸ A separate cross-sectional study of asymptomatic people at a rapid screening service found an overall Mycoplasma genitalium prevalence of about 7.4%.⁹

What makes this pathogen particularly worrisome is antibiotic resistance. In the Zurich cohort, about 73% of Mycoplasma genitalium infections were resistant to macrolide antibiotics, the usual first-line treatment.⁸ The cross-sectional study found a similarly high macrolide resistance rate of about 70% among men who have sex with men, though resistance was much lower (about 10%) among heterosexual participants.⁹ Because most infections produce no symptoms and the first-choice antibiotic often fails, silent Mycoplasma genitalium can circulate for long periods in a population. Routine testing for it is not yet standard in most countries, which compounds the problem.

Why So Many STIs Stay Silent

It is not a coincidence that so many sexually transmitted pathogens have long asymptomatic windows. There is a straightforward evolutionary logic at work. An infection that immediately makes its host visibly sick prompts that person to seek treatment or avoid sex, which cuts off the pathogen’s route to new hosts. Organisms that produce few or no symptoms for extended periods have more opportunities to spread, so over generations, natural selection favors milder or more covert infection strategies.¹⁰ This helps explain why the list of STIs with major asymptomatic phases is so long: chlamydia, gonorrhea, HPV, herpes, trichomoniasis, syphilis, HIV, and Mycoplasma genitalium all gain a transmission advantage from stealth.

The human immune system, for its part, often mounts a response that controls but does not eliminate these pathogens. HSV-2 retreats into nerve cells where the immune system cannot reach it, re-emerging periodically. HPV nestles into the deepest layer of skin cells and keeps its protein expression turned down, only ramping up viral production as cells migrate toward the surface. Chlamydia can persist intracellularly, triggering chronic low-grade inflammation that damages tissue without producing the acute symptoms that would send someone to a clinic. The result is a standoff: the immune system limits the infection enough to keep the host functional, but the pathogen persists long enough to find new hosts.

What Happens When Silent Infections Go Untreated

The danger of asymptomatic STIs is not the infection itself so much as what it does over time. Most cases of tubal factor infertility are caused by untreated sexually transmitted infections that ascend into the reproductive tract and cause inflammation, scarring, and structural damage to the fallopian tubes.¹¹ Chlamydia is the primary culprit. When chlamydial infections go unresolved, the bacteria can ascend from the cervix to the fallopian tubes, triggering salpingitis and a cascade of immune responses that leads to fibrosis and blockage of the tubes.¹² An estimated 10% of women with chlamydial infection develop pelvic inflammatory disease, which can occur at any point during the infection rather than only at its outset.¹³ Because the infection may be completely asymptomatic throughout, the first sign of trouble can be difficulty getting pregnant years later.

Pregnancy itself creates additional stakes. Syphilis, when active during pregnancy, can be transmitted to the fetus with severe consequences. In a population-based cohort from northern Australia, babies born with congenital syphilis had more than three times the risk of preterm birth and more than double the risk of being small for gestational age compared with unaffected births.¹⁴ Syphilis has a prolonged latent phase during which there are no visible symptoms at all, making routine prenatal screening the only reliable way to catch it in time to treat before the fetus is affected.

The Vaginal Microbiome Connection

Your vulnerability to picking up an STI, and how easily you might transmit one, is influenced by the bacterial community in the genital tract. Bacterial vaginosis, a common disruption of the vaginal microbiome in which protective Lactobacillus species are depleted, has been linked to increased genital shedding of HIV. One study found that women with diminished Lactobacillus levels had roughly 16-fold greater endocervical HIV RNA levels compared with women whose Lactobacillus populations were healthy.¹⁵ Higher genital viral load translates directly to a higher chance of transmitting the virus to a partner.

Bacterial vaginosis itself is often asymptomatic, which sets up a compounding problem: a person with no symptoms of BV has a microbiome that makes them more susceptible to acquiring other STIs, and if they do acquire HIV or another infection, they may shed more of it genitally. This silent synergy between a disrupted microbiome and asymptomatic STIs means that the biological landscape is often working against early detection on multiple fronts simultaneously.

How Home Testing Is Changing the Equation

One of the biggest practical barriers to catching asymptomatic STIs is that people who feel fine tend not to visit a clinic for screening. Home-based specimen collection has emerged as a way to close that gap. Research has consistently shown that when people are offered the option to self-collect specimens at home, testing rates go up substantially. In randomized trials, participants offered home collection were roughly two and a half to three times more likely to actually get tested compared with those directed to a clinic.¹⁶¹⁷ This makes intuitive sense: collecting a urine sample or vaginal swab at home is more convenient and less embarrassing than scheduling a clinic appointment.

Because home testing captures people who would otherwise skip screening entirely, it tends to find more asymptomatic infections in absolute terms. A meta-analysis found a higher proportion of positive chlamydia tests among people who collected specimens at home compared with those tested in clinics, likely because the home-tested group included more asymptomatic individuals who would not have sought clinical care.¹⁶ Making low-cost home test kits available could be especially valuable for younger people and those in underserved areas who face logistical or financial barriers to clinic-based care.¹⁸

The Economics of Screening People Who Feel Fine

Screening people without symptoms costs money upfront, and health systems want to know if the investment is worth it. The answer depends on which infection and which population you are talking about. For chlamydia and gonorrhea screening in young people visiting emergency departments, targeted screening detected about a quarter of STI cases that would otherwise have been missed, and the cost per case found was economically favorable. Expanding to universal screening in that same setting found somewhat more cases but at roughly double the cost per additional case detected.¹⁹

Trichomoniasis presents a split picture. During pregnancy, universal screening looks like a bargain because the downstream costs of preterm birth and neonatal complications are so high.⁷ Outside of pregnancy, however, screening asymptomatic women for trichomoniasis with molecular testing has been estimated at over $400,000 per quality-adjusted life-year gained, well above typical willingness-to-pay thresholds.²⁰ These kinds of calculations help explain why screening recommendations differ so much from one STI to the next, and why blanket “test for everything” approaches are not always the standard of care even when we know an infection is common and often silent.

Who Should Be Getting Screened and When

If you are sexually active, the most practical takeaway from all of this is that you cannot rely on symptoms to tell you whether you have an STI. The infections most likely to cause long-term damage are the ones least likely to announce themselves. Current guidelines in the United States generally recommend annual chlamydia and gonorrhea screening for sexually active women under 25, and for older women with risk factors like new or multiple partners. Men who have sex with men are recommended for more frequent screening, including for syphilis and HIV, given the higher prevalence of asymptomatic infections in that population. A study of HIV-positive men who have sex with men found that 16% had an undiagnosed STI detected through screening alone.²¹

For HPV, cervical screening with Pap tests or HPV co-testing typically starts at age 21 or 25 depending on the country and continues at regular intervals. Herpes blood testing is not part of routine panels because the clinical value of diagnosing asymptomatic HSV-2 remains debated: knowing you carry the virus does not change treatment unless you have outbreaks, and the psychological burden of diagnosis is real. Mycoplasma genitalium testing is growing in availability but is not yet part of standard panels in most settings. If you have persistent or recurrent urethritis or cervicitis that does not respond to standard treatment, your clinician may test for it specifically.

The recurring theme across every one of these infections is that waiting for symptoms is not a reliable strategy. The biology of these organisms has been shaped, over millennia, to keep you feeling fine while transmission continues. Screening is the countermeasure, and knowing which tests to ask for, and how often, is the most effective thing you can do to stay ahead of infections you would never otherwise know you had.

1
PubMed. Asymptomatic sexually transmitted diseases: the case for screening
2
PubMed. Rates of asymptomatic nonurethral gonorrhea and chlamydia in a population of university men who have sex with men
3
PubMed Central. Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons with HSV-2 Infection
4
Clinical Science. Molecular biology of human papillomavirus infection and cervical cancer
5
PubMed Central. Analysis of risk factors for persistent infection of asymptomatic women with high-risk human papilloma virus
6
PubMed Central. Prevalence of Trichomonas vaginalis infection in Kashan city, Iran (2012-2013)
7
Obstetrics & Gynecology. Cost Effectiveness of Routine Screening of Vaginal Trichomoniasis in Pregnant People
8
PubMed Central. High Rates of Asymptomatic Mycoplasma genitalium Infections With High Proportion of Genotypic Resistance to First-Line Macrolide Treatment Among Men Who Have Sex With Men Enrolled in the Zurich Primary HIV Infection Study
9
Sexually Transmitted Infections. Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study
10
Southern African Journal of Infectious Diseases. Sexually transmitted pathogens in asymptomatic women at Rethabile clinic, Limpopo, South Africa
11
PubMed Central. Sexually transmitted diseases and infertility
12
PubMed. Pathogenesis of fallopian tube damage caused by Chlamydia trachomatis infections
13
PubMed Central. Timing of progression from Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study
14
The Lancet Regional Health – Western Pacific. The association between sexually transmitted infections and pregnancy outcomes in the Northern Territory, Australia: a population-based cohort study
15
JCI Insight. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective
16
BMJ. At-home specimen self-collection as an additional testing strategy for chlamydia and gonorrhoea: a systematic literature review and meta-analysis
17
Sexually Transmitted Infections. Self-collection of samples as an additional approach to deliver testing services for sexually transmitted infections: a systematic review and meta-analysis
18
PubMed Central. Screening for sexually transmitted infections at home or in the clinic?
19
PubMed Central. Cost-effectiveness of Sexually Transmitted Infection Screening for Adolescents and Young Adults in the Pediatric Emergency Department
20
PubMed. Cost-Effectiveness of Testing and Screening Strategies for Trichomoniasis among Asymptomatic and Symptomatic Women in U.S. Outpatient Clinical Settings
21
PubMed. High prevalence of asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: a stimulus to improve screening